-
RTOG 9408- A PHASE III TRIAL OF THE
STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT
PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED
ADENOCARCINOMA OF THE PROSTATE
Closed to accrual
-
RTOG 9902- A PHASE III PROTOCOL OF
ANDROGEN SUPPRESSION (AS) AND RADIATION THERAPY (RT) VS AS
AND RT FOLLOWED BY CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND
ETOPOSIDE (TEE) FOR LOCALIZED, HIGH-RISK, PROSTATE CANCER
PI Dr.
Ivan Kessel Eligibility
Schema
-
RTOG-9910-
A PHASE III TRIAL TO
EVALUATE THE DURATION OF NEOADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)
AND RADIATION THERAPY (RT) IN INTERMEDIATE-RISK PROSTATE CANCER
PI Dr.
Ivan Kessel Eligibility
Schema
-
RTOG P-0011 PHASE III RANDOMIZED STUDY OF ADJUVANT THERAPY FOR
HIGH RISK pT2-3N0 PROSTATE CANCER
Eligibility
Schema
-
RTOG P-0126;
A PHASE III RANDOMIZED STUDY OF HIGH DOSE
3D-CRT VERSUS STANDARD DOSE 3D-CRT IN PATIENTS TREATED FOR LOCALIZED PROSTATE CANCER
Eligibility
Schema
-
RTOG 96-01 A PHASE III TRIAL OF RADIATION THERAPY
WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL
PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE
Eligibility Schema
THIS PROTOCOL IS CLOSED
-
RTOG P-0014 A PHASE III
RANDOMIZED STUDY OF PATIENTS WITH HIGH RISK, HORMONE-NAÏVE PROSTATE
CANCER: ANDROGEN BLOCKADE WITH 4 CYCLES OF IMMEDIATE CHEMOTHERAPY VERSUS
ANDROGEN BLOCKADE WITH DELAYED CHEMOTHERAPY
Eligibility
Schema
-
RTOG 0233 A
PHASE II RANDOMIZED TRIAL FOR PATIENTS WITH MUSCLE-INVADING BLADDER
CANCER EVALUATING TRANSURETHRAL SURGERY AND BID IRRADIATION PLUS EITHER
PACLITAXEL AND CISPLATIN OR 5-FLUOROURACIL AND CISPLATIN FOLLOWED BY
SELECTIVE BLADDER PRESERVATION AND GEMCITABINE/PACLITAXEL/CISPLATIN
ADJUVANT CHEMOTHERAPY
Eligibility
Schema
